Conference
Neutropenia as a potential pharmacodynamic marker for docetaxel-based chemotherapy in men with metastatic castration-resistant prostate cancer (mCRPC).
Abstract
51
Background: Data suggest docetaxel clearance is increased in castrate men. An association of docetaxel-induced grade ≥3 neutropenia with overall survival (OS) may provide a rationale for tailored dosing in mCRPC.
Authors
Pond GR; Berry WR; Galsky MD; Wood BA; Leopold LH; Sonpavde G
Volume
30
Pagination
pp. 51-51
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
February 10, 2012
DOI
10.1200/jco.2012.30.5_suppl.51
Conference proceedings
Journal of Clinical Oncology
Issue
5_suppl
ISSN
0732-183X